Oncology Institute, Inc. - Common Stock, par value $0.0001 per share (TOI) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
TOI on Nasdaq
Shares outstanding
87,441,936
Price per share
$2.86
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
38,475,289
Total reported value
$137,091,418
% of total 13F portfolios
0%
Share change
+3,787,568
Value change
+$13,634,767
Number of holders
115
Price from insider filings
$2.86
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Oncology Institute, Inc. - Common Stock, par value $0.0001 per share (TOI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SARIN RAVI YANG 4.7% $11,959,434 4,109,771 Ravi Sarin 26 Mar 2025

As of 31 Dec 2025, 115 institutional investors reported holding 38,475,289 shares of Oncology Institute, Inc. - Common Stock, par value $0.0001 per share (TOI). This represents 44% of the company’s total 87,441,936 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Oncology Institute, Inc. - Common Stock, par value $0.0001 per share (TOI) together control 39% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 5.4% 4,748,635 +4.5% 0% $16,905,141
BlackRock, Inc. 4.5% 3,905,333 +14% 0% $13,902,986
DEERFIELD MANAGEMENT COMPANY, L.P. 3.8% 3,360,052 0% 0.15% $11,961,785
CenterBook Partners LP 3.5% 3,029,312 +12% 0.53% $10,784,351
Kanen Wealth Management LLC 3.4% 2,976,144 +62% 3.3% $10,712,000
Balyasny Asset Management L.P. 2.9% 2,518,437 +0% 0.02% $8,965,636
JOSH ARNOLD INVESTMENT CONSULTANT, LLC 2.8% 2,459,809 +1104% 6.7% $8,756,920
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,570,454 +12% 0% $5,592,185
WEXFORD CAPITAL LP 1.8% 1,533,456 -2.4% 1.4% $5,459,100
STATE STREET CORP 1.5% 1,351,624 +20% 0% $4,811,781
JANE STREET GROUP, LLC 0.92% 803,315 +543% 0% $2,859,802
RENAISSANCE TECHNOLOGIES LLC 0.83% 721,900 -3.8% 0% $2,569,964
BRC Group Holdings, Inc. 0.76% 663,376 -18% 1% $2,361,619
GOLDMAN SACHS GROUP INC 0.65% 570,424 -16% 0% $2,030,709
NORTHERN TRUST CORP 0.57% 499,244 +7.4% 0% $1,777,308
Massar Capital Management, LP 0.46% 400,000 0% 0.28% $1,424,000
JPMORGAN CHASE & CO 0.44% 386,778 +1483% 0% $1,376,930
FourWorld Capital Management LLC 0.44% 382,700 +6.9% 1.3% $1,362,412
GatePass Capital, LLC 0.41% 360,000 0.66% $1,281,600
FreeGulliver LLC 0.41% 355,672 +69% 0.57% $1,266,192
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.34% 295,150 0% $1,050,734
UBS Group AG 0.33% 287,686 -73% 0% $1,024,162
LPL Financial LLC 0.31% 270,885 +1.5% 0% $964,351
TWO SIGMA INVESTMENTS, LP 0.3% 262,050 -6.1% 0% $932,898
Maven Securities LTD 0.29% 251,128 +151% 0.11% $894,016

Institutional Holders of Oncology Institute, Inc. - Common Stock, par value $0.0001 per share (TOI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 38,475,289 $137,091,418 +$13,634,767 $3.56 115
2025 Q3 34,670,910 $120,993,806 +$10,399,257 $3.49 107
2025 Q2 31,474,503 $64,523,702 +$31,211,552 $2.05 78
2025 Q1 16,901,932 $19,267,414 +$2,727,938 $1.14 42
2024 Q4 14,712,600 $4,608,917 -$2,191,797 $0.31 30
2024 Q3 20,589,694 $6,982,762 +$385,704 $0.33 34
2024 Q2 18,701,866 $8,832,828 -$155,334 $0.46 38
2024 Q1 17,222,037 $27,535,675 -$2,492,260 $1.58 44
2023 Q4 18,436,129 $37,608,749 +$6,554,810 $2.04 44
2023 Q3 15,107,160 $21,169,015 +$1,157,191 $1.40 36
2023 Q2 13,916,345 $7,656,692 -$4,490,020 $0.55 37
2023 Q1 21,905,923 $14,849,314 -$1,309,674 $0.68 37
2022 Q4 23,473,725 $38,730,078 -$1,269,944 $1.65 37
2022 Q3 23,327,364 $108,006,612 +$6,672,135 $4.63 39
2022 Q2 21,874,386 $110,684,000 +$2,844,383 $5.06 33
2022 Q1 17,791,143 $126,852,000 -$752,294 $7.13 27
2021 Q4 21,118,138 $199,883,000 +$185,679,000 $9.75 21
2021 Q3 252,439 $2,504,000 +$2,504,000 $9.92 1